BRAIN Publication-derived

APOE4 Cerebral Organoid Model for Alzheimer Disease

Source Lin et al. · Massachusetts Institute of Technology (MIT), Cambridge, MA, USA · 10.1016/j.neuron.2018.05.008

👤 Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penber J, Bhatt NP, Bhatt SM, Bhatt RS, Bhatt AH, Bhatt RM, Bhatt KJ, Bhatt AM, Bhatt JE, Bhatt MN, Bhatt AB, Bhatt RN, Bhatt F, Bhatt KM, Tsai LH ⏱ 43200 min 🧫 Patient-Derived iPSC (APOE4/4) / Isogenic APOE3/3 Controls

Abstract

Lin et al. used CRISPR gene editing to generate isogenic APOE4/4 and APOE3/3 cerebral organoids, demonstrating that APOE4 drives increased amyloid-β accumulation, tau hyperphosphorylation, and cholesterol metabolism dysregulation independently of other genetic background effects. This Neuron 2018 study established the isogenic approach as the gold standard for studying APOE4 as an Alzheimer disease risk factor.

Cell source

Patient-Derived iPSC (APOE4/4) / Isogenic APOE3/3 Controls

Application

Sporadic Alzheimer Disease Modeling

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Lin et al.. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?

Use this protocol in your therapeutic or diagnostic pipeline.

Request Commercial Licence